GENETIC PRE-PARTICIPATION SCREENING IN SELECTED ATHLETES: A NEW TOOL FOR THE PREVENTION OF SUDDEN CARDIAC DEATH?


(1) Department of Biochemistry and Medical Biotechnologies, University of Naples Federico II, Naples, Italy and CEINGEBiotecnologie Avanzate, Naples, Italy
(2) Cardiomyopathy and Inherited Heart Disease Clinic, Osservatorio Epidemiologico della Medicina dello Sport della Regione Campania, Naples, Italy
(3) Cardiology, Second University of Naples, Naples, Italy
(4) Cardiology, Department of Internal Medicine and Public Health, University of L’Aquila, Italy
(5) Institute of Sport Medicine and Science, CONI, Rome, Italy
(6) CEINGE-Biotecnologie Avanzate, Naples, Italy and IRCCSFondazione SDN, Naples, Italy

Background: Sudden cardiac death (SCD) of athletes is a topical issue. “Borderline cardiac abnormalities”, which occur in ~2% of elite male athletes, may result in SCD, which may have a genetic base. Genetic analysis may help identify pathological cardiac abnormalities. We performed phenotype-guided genetic analysis in athletes who, pre-participation, showed ECG and/or echo “borderline” abnormalities, to discriminate subjects at a greater risk of SCD.

Methods: We studied 24 elite athletes referred by the National Federation of Olympic sports; and 25 subjects seeking eligibility to practice agonistic sport referred by the Osservatorio Epidemiologico della Medicina dello Sport della Regione Campania. Inclusion criteria: a) ECG repolarization borderline abnormalities; b) benign ventricular arrhythmias; c) left ventricular wall thickness in the grey zone of physiology versus pathology (max wall thickness 12-15 mm in females; 13-16 mm in males). Based on the suspected phenotype, we screened subjects for the LMNA gene, for 8 sarcomeric genes, 5 desmosomal genes, and cardiac calcium, sodium and potassium channel disease genes.

Results: Genetic analysis was completed in 37/49 athletes, 22 competitive and 27 non-competitive athletes, showing “borderline” clinical markers suggestive of hypertrophic cardiomyopathy (HCM, n. 24), dilated cardiomyopathy (n. 4), arrhythmogenic right ventricular dysplasia/catecholaminergic polymorphic ventricular tachycardia (ARVD/CPVT, n. 11), long QT syndrome (LQTS, n. 4), sick sinus syndrome (SSS, n. 5), Brugada syndrome (BrS, n. 1). We identified 11 mutations in 9 athletes (an ARVD athlete was compound heterozygote for the PKP2 gene and an HCM athlete was double heterozygote for the MYBPC3 and TNN1 genes): 3 known mutations related to LQTS, HCM and ARVD, respectively, and 8 novel mutations, located in the SCN5A, RyR2, PKP2, MYBPC3 and ACTC1 genes. The new mutations were absent in ~800 normal chromosomes and were predicted “probably damaging” by in silico analysis. Patch clamp analysis in channelopathies indicated for some mutation abnormal biophysical behavior of the corresponding mutant protein.

Conclusion: Genetic analysis may help distinguish between physiology and pathology in athletes with clinically suspected heart disease.